Smith Brendan
SEC CIK 1857492 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | CFO | 5,072 | — | — | 4 | 2022-10-14 | 2023-02-21 |
Most active insiders at CRSP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Kulkarni Samarth | CEO, Dir | — | $10.76M |
| 2 | Prasad Raju | CFO | — | $5.10M |
| 3 | KASINGER JAMES R. | GC, Sec | — | $1.27M |
| 4 | Behbahani Ali | Dir | — | $780.9K |
| 5 | Patel Naimish | Chief Medical Off | — | $362.6K |
Smith Brendan made no open-market trades at CRSP in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-22 | 2023-02-21 | CRSP | CRISPR Therapeutics AG | Smith Brendan | CFO | F - Tax | $48.26 | -1,392 | 5,072 | -22% | -$67.2K |
| D | 2023-02-22 | 2023-02-18 | CRSP | CRISPR Therapeutics AG | Smith Brendan | CFO | M - OptEx | — | +3,825 | 6,464 | +145% | — |
| D | 2022-10-18 | 2022-10-17 | CRSP | CRISPR Therapeutics AG | Smith Brendan | CFO | F - Tax | $55.76 | -1,111 | 2,639 | -30% | -$61.9K |
| D | 2022-10-18 | 2022-10-14 | CRSP | CRISPR Therapeutics AG | Smith Brendan | CFO | M - OptEx | — | +3,750 | 3,750 | New | — |
Purchase Sale Sale after option exercise All abbreviations